scholarly article | Q13442814 |
P356 | DOI | 10.1016/S0735-1097(98)00532-4 |
P698 | PubMed publication ID | 9935015 |
P2093 | author name string | N S Kleiman | |
C W Smith | |||
B J Hughes | |||
M N Ali | |||
J K Mickelson | |||
T W Chow | |||
N M Lakkis | |||
P2860 | cites work | A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group | Q28245560 |
Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm | Q29547181 | ||
Chemotactic factors regulate lectin adhesion molecule 1 (LECAM-1)-dependent neutrophil adhesion to cytokine-stimulated endothelial cells in vitro | Q34237390 | ||
Recruitment of CD11b/CD18 to the neutrophil surface and adherence-dependent cell locomotion | Q35608005 | ||
P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin | Q36382391 | ||
Motility and adhesiveness in human neutrophils. Effects of chemotactic factors | Q37035630 | ||
In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function | Q37273254 | ||
Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor | Q37373855 | ||
Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a "magic bullet". | Q37773499 | ||
The basis of molecular strategies for treating coronary restenosis after angioplasty | Q40749553 | ||
Defining coronary restenosis. Newer clinical and angiographic paradigms | Q40836276 | ||
7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. | Q41123265 | ||
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization | Q44612131 | ||
PTCA: periprocedural platelet activation. Part II of the Duesseldorf PTCA platelet study (DPPS) | Q52521791 | ||
Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. | Q53366355 | ||
Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. | Q55060856 | ||
Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months | Q56945638 | ||
Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets | Q59065667 | ||
Modulation of Platelet Surface Adhesion Receptors during Cardiopulmonary Bypass | Q67702157 | ||
Granulocyte activation after coronary angioplasty in humans | Q68466449 | ||
Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death | Q70014087 | ||
Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion | Q70058588 | ||
Platelet function in acute myocardial infarction treated with direct angioplasty | Q70866651 | ||
Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study | Q70908805 | ||
Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty | Q71038217 | ||
Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content | Q71102869 | ||
Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease? | Q71518090 | ||
Increased neutrophil-platelet adhesion in patients with unstable angina | Q71571191 | ||
Long-term (4- to 6-year) outcome of Palmaz-Schatz stenting: paucity of late clinical stent-related problems | Q71606924 | ||
Neutrophil activation after percutaneous transluminal coronary angioplasty | Q71660707 | ||
Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty | Q71724509 | ||
Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors | Q71827452 | ||
Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease | Q72227001 | ||
Modulation of the expression of the granulocyte adhesion molecule, CR3, by percutaneous transluminal coronary angioplasty and contrast media | Q72402603 | ||
Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment | Q72571519 | ||
Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology | Q72708405 | ||
Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty | Q72726624 | ||
Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty | Q73310480 | ||
Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets | Q73384671 | ||
Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy | Q73951493 | ||
Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease | Q74172108 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | angioplasty | Q539795 |
P304 | page(s) | 97-106 | |
P577 | publication date | 1999-01-01 | |
P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
P1476 | title | Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty | |
P478 | volume | 33 |
Q37316783 | A bumpy and winding but right path to domestic drug-eluting coronary stents |
Q28196075 | Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation |
Q28165999 | Adjunctive Pharmacotherapy before Percutaneous Coronary Intervention in Non-ST-Elevation Acute Coronary Syndromes: The Role of Modulating Inflammation |
Q37221177 | Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model |
Q38521611 | Effect of abciximab on myocardial salvage in patients with acute myocardial infarction undergoing primary angioplasty. |
Q43264728 | Effect of high bolus dose tirofiban on the inflammatory response following percutaneous coronary intervention |
Q42238584 | Evolving coronary stents coated with new bioactive agents |
Q73740288 | IIb's are not IIb's |
Q47437758 | Inflammation as a therapeutic target: a unique role for abciximab |
Q58411837 | Inhibition by soya isoflavones of human polymorphonuclear leukocyte function: possible relevance for the beneficial effects of soya intake |
Q51798983 | Material‐induced tissue factor expression but not CD11b upregulation depends on the presence of platelets |
Q44346890 | Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization |
Q64106613 | Neutrophils disturb pulmonary microcirculation in sepsis-induced acute lung injury |
Q35090367 | Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction |
Q34875121 | Oxidative stress and neutrophil activation--the two keystones of ischemia/reperfusion injury. |
Q33862443 | Platelets and restenosis |
Q36679440 | Rationale for intracoronary administration of abciximab |
Q33933810 | Reperfusion injury after focal myocardial ischaemia: polymorphonuclear leukocyte activation and its clinical implications |
Q56944889 | The benefit of abciximab in percutaneous coronary revascularization is not device-specific |
Q35936923 | The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab: Reopro) coated stent in patients with coronary artery disease |